Amylyx Pharmaceuticals, Inc. (AMLX) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Amylyx Pharmaceuticals, Inc. (AMLX) closed at USD 27.03 on 2026-10-14, a change of +88.8 % over the past year, with a market capitalization of USD 3.47B.

Amylyx Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Amylyx Pharmaceuticals, Inc. key figures

Previous close

USD 27.03 (2026-10-14)

1-year change

+88.8 %

Market cap

USD 3.47B

Enterprise value

USD 2.84B

P/E ratio (trailing)

-19.07

P/E ratio (forward)

-25.36

EPS (trailing)

-1.45

EPS (forward)

-1.09

PEG ratio

n/a

Price to book

12.87

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.18

Employees

136

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Amylyx Pharmaceuticals, Inc. and compare it with other stocks.